{"disease":{"id":"generalized-myasthenia-gravis","name":"Generalized myasthenia gravis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":12},"drugs":{"marketed":[{"drug_id":"ravulizumab","indication_name":"Generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultomiris","generic_name":"RAVULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitor [EPC]","quality_score":75,"revenue":"5100","mechanism":"Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells."},{"drug_id":"nipocalimab","indication_name":"Generalized Myasthenia Gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imaavy","generic_name":"NIPOCALIMAB","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG."},{"drug_id":"nipocalimab","indication_name":"generalized myasthenia gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imaavy","generic_name":"NIPOCALIMAB","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG."},{"drug_id":"nipocalimab","indication_name":"generalized myasthenia gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imaavy","generic_name":"NIPOCALIMAB","company_name":"Janssen Biotech","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Imaavy works by binding to and blocking the activity of certain immune cells that mistakenly attack healthy nerve-muscle connections in people with gMG."},{"drug_id":"eculizumab","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"H5G1.1","generic_name":"ECULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":56,"revenue":null,"mechanism":"Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation."},{"drug_id":"rozanolixizumab-noli","indication_name":"Generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RYSTIGGO","generic_name":"ROZANOLIXIZUMAB-NOLI","company_name":"UCB INC","drug_phase":"marketed","molecular_target":"IgG receptor FcRn large subunit p51","drug_class":"Neonatal Fc Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ravulizumab-cwvz","indication_name":"Generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ULTOMIRIS","generic_name":"RAVULIZUMAB-CWVZ","company_name":"ALEXION PHARM","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ultomiris","indication_name":"Generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ultomiris","company_name":"Alexion Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"eculizumab-aeeb","indication_name":"Generalized Myasthenia Gravis (gMG)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BKEMV","generic_name":"ECULIZUMAB-AEEB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Complement Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"soliris","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Soliris","company_name":"Apellis Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT06617741","title":"Myasthenia Gravis Foundation of America Global MG Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3800,"lead_sponsor_name":"Myasthenia Gravis Foundation of America","has_results":false},{"nct_id":"NCT04202341","title":"Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07247279","title":"Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05070858","title":"A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":288,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06463587","title":"Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":264,"lead_sponsor_name":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT05556096","title":"Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":261,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04225871","title":"Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT03971422","title":"A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT04963270","title":"A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04818671","title":"Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":184,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT06744920","title":"A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03920293","title":"Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03669588","title":"An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT04650854","title":"A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":165,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT03770403","title":"A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT06517758","title":"A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02301624","title":"Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04735432","title":"Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"argenx","has_results":true},{"nct_id":"NCT06447597","title":"A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","has_results":false},{"nct_id":"NCT07221838","title":"A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06312644","title":"Study of Ultomiris® (Ravulizumab) Safety in Pregnancy","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04124965","title":"A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT07284420","title":"ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT07294170","title":"ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT05218096","title":"Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04980495","title":"An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT03772587","title":"A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Momenta Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05681715","title":"A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT02950155","title":"A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Fredrik Piehl","has_results":true},{"nct_id":"NCT03315130","title":"Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Ra Pharmaceuticals","has_results":true},{"nct_id":"NCT06967480","title":"Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03896295","title":"An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"Momenta Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06471361","title":"A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT05214612","title":"Predictors and Prognostic Factors of Myasthenia Gravis Outcome","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05514873","title":"An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT06759948","title":"An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Chongbo Zhao","has_results":false},{"nct_id":"NCT06764160","title":"Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07215949","title":"Zilucoplan for Severe gMG Exacerbations","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Miriam Freimer","has_results":false},{"nct_id":"NCT06704269","title":"Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06987539","title":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06540144","title":"An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":12,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT06392386","title":"A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"argenx","has_results":false},{"nct_id":"NCT05644561","title":"Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06149559","title":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT06607627","title":"PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06055959","title":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":8,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT06435312","title":"An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":8,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT07058298","title":"GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Daishi Tian","has_results":false},{"nct_id":"NCT04982289","title":"Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}